131I SPECT/CT为分化型甲状腺癌患者提供预后信息
该回顾性研究纳入942例分化型甲状腺癌患者,首次放射性碘治疗后行颈部131I SPECT/CT,按CT大小和131I摄取对淋巴结转移分类。无淋巴结转移者完全缓解中位时间更短(9.4个月 vs 44个月,HR 2.2;p<0.01)且进展风险更低(HR 0.46;p<0.01)。结论认为无淋巴结转移者更可能早期完全缓解和更长无进展生存,有淋巴结转移者可受益于早期再手术,治疗策略应基于淋巴结特征个体化。
要点
- 无淋巴结转移者完全缓解中位时间9.4个月,有淋巴结转移者44个月(HR 2.2;p<0.01)。
- 无淋巴结转移者进展风险更低(HR 0.46;p<0.01),小淋巴结转移者无进展生存与无转移者相似(HR 1.22;p=0.54)。
- 增大淋巴结转移者首次放射性碘治疗后早期再手术(13.5个月)较第二次放射性碘治疗更早完全缓解。
核心结论
- 首次放射性碘治疗后131I SPECT/CT上无淋巴结转移的患者有更好的早期完全缓解机会和更长无进展生存。
- 有淋巴结转移的患者受益于早期再手术,但治疗策略应基于淋巴结特征个体化制定。
研究设计与样本
- 回顾性研究,纳入942例分化型甲状腺癌患者,均在首次放射性碘治疗后行颈部131I SPECT/CT。
- 淋巴结转移按CT大小(增大≥1 cm,小<1 cm)和131I摄取分类,采用Kaplan-Meier曲线和Cox回归分析完全缓解和无进展生存。
主要发现
- 无淋巴结转移者完全缓解中位时间9.4个月,有淋巴结转移者44个月(HR 2.2;p<0.01);无淋巴结转移者进展风险更低(中位无进展生存未达到,HR 0.46;p<0.01)。
- 有淋巴结转移者中,增大且131I阴性淋巴结转移者完全缓解时间最长(24个月,HR 0.36;p<0.01)。
- 小淋巴结转移者无进展生存与无淋巴结转移者相似(中位无进展生存未达到,HR 1.22;p=0.54)。
- 增大淋巴结转移者中,首次放射性碘治疗后再次手术(13.5个月)较第二次放射性碘治疗(中位未达到)更早完全缓解。
- 小淋巴结转移者中,第二次放射性碘治疗较再次手术无进展生存更长(38.4个月 vs 未达到,HR 4.0;p=0.02)。
临床怎么用
- 作者认为无淋巴结转移患者有更好的早期完全缓解机会和更长无进展生存。
- 作者认为有淋巴结转移患者受益于早期再手术,但治疗策略应基于淋巴结特征个体化制定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study is to investigate the impact of lymph node metastases (LNM) detected on cervical 131I single photon emission computed tomography/computed tomography (SPECT/CT) after the first radioiodine therapy (RAI) on complete response (CR) and progression-free survival (PFS) in patients with differentiated thyroid cancer (DTC). METHODS: This retrospective study included 942 DTC patients who underwent cervical 131I SPECT/CT after their first RAI. LNM were categorized based on CT (enlarged ≥ 1 cm, small < 1 cm) and 131I uptake. CR and PFS were analysed using Kaplan-Meier curves and Cox regression. RESULTS: Patients with no LNM had a shorter median time to CR (9.4 months) than those with LNM (44 months, HR 2.2; p < 0.01) and a lower risk of progression (median PFS not reached, HR 0.46; p < 0.01). Among patients with LNM, those with enlarged 131I negative LNM had the longest time to CR (24 months, HR 0.36; p < 0.01). Patients with small LNM had a PFS similar to patients without LNM (median PFS not reached, HR 1.22; p = 0.54). Reoperation after first RAI (13.5 months) led to earlier CR than second RAI (median not reached) in patients with enlarged LNM. For small LNM, second RAI was associated with longer PFS than reoperation (38.4 months vs. not reached, HR 4.0; p = 0.02). CONCLUSION: Patients without LNM on post-therapy 131I SPECT/CT have better chances for early CR and longer PFS. Patients with LNM benefit from early reoperations but treatment strategies should be tailored based on LNM characteristics.
引用
- Heinrich M, Blickle E, Hartrampf PE, et al. 131I SPECT/CT provides prognostic information in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40088267. doi:10.1007/s00259-025-07187-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。